

1. Name: Byung Sik Cho

2. Affiliation/Current Position

Department of Hematology, Catholic Hematology Hospital, Leukemia Research Center, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea/ Professor

3. Country: Republic of Korea

4. Educational Background:

Bachelor's degree	Catholic University of Korea, Seoul, Korea, 1992-1998
Master of Medical Science	Catholic University of Korea, Seoul, Korea, 2006-2008
Doctor of Medical Science	Catholic University of Korea, Seoul, Korea, 2008-2011

5. Professional Experiences:

May.2006 - Feb. 2009	Clinical and Research Fellow Department of Hematology, Catholic Hematopoietic Stem Cell Transplantation Center, St. Mary's Hospital, CUK, Seoul, Korea
Mar. 2009 - Feb. 2010	Clinical Assistant Professor, Department of Hematology, Catholic Blood and Marrow Transplantation Center, Seoul St. Mary's Hospital, CUK, Seoul, Korea
Mar. 2010 – Mar. 2013	Assistant Professor, Department of Hematology, Catholic Blood and Marrow Transplantation Center, Seoul St. Mary's Hospital, CUK, Seoul, Korea
April. 2013 – 2019	Associate Professor, Department of Hematology, Catholic Blood and Marrow Transplantation Center, Seoul St. Mary's Hospital, CUK, Seoul, Korea
April. 2013 – Feb. 2015	Visiting Scholar, Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Oct. 2015 – Present	Adjunct Associate Professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
April. 2019 –Present	Professor, Department of Hematology,

Catholic Hematology Hospital,

Seoul St. Mary's Hospital, CUK, Seoul, Korea

6. Professional Organizations

Department of Hematology, Catholic Hematology Hospital, Leukemia Research Center, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea

7. Main Scientific Publications (as first or corresponding author, since 2019):

- Kim HJ, Kim Y, Kang D, Kim HS, Lee JM, Kim M, **Cho BS**. Prognostic value of measurable residual disease monitoring by next-generation sequencing before and after allogeneic hematopoietic cell transplantation in acute myeloid leukemia. *Blood Cancer J*. 2021 Jun 4;11(6):109.
- **Cho BS**, Yahng SA, Min GJ, Park S, Park SS, Shin SH, Jeon YW, Yoon JH, Lee SE, Eom KS, Kim YJ, Lee S, Min CK, Cho SG, Kim DW, Lee JW, Kim M, Kim Y, Kim HJ. Comparable outcomes after alternative and matched sibling donor hematopoietic stem cell transplantation and the role of molecular measurable residual disease for acute myeloid leukemia in elderly patients. *Transplant Cell Ther*. 2021 May 31:S2666-6367(21)00943-X. doi: 10.1016/j.jtct.2021.05.024. Online ahead of print.
- **Cho BS**, Min GJ, Park SS, Park S, Jeon YW, Shin SH, Yahng SA, Yoon JH, Lee SE, Eom KS, Kim YJ, Lee S, Min CK, Cho SG, Kim DW, Wook-Lee J, Kim MS, Kim YG, Kim HJ. Prognostic Impacts of D816V KIT Mutation and Peri-Transplant RUNX1-RUNX1T1 MRD Monitoring on Acute Myeloid Leukemia with RUNX1-RUNX1T1. *Cancers (Basel)*. 2021 Jan 18;13(2):E336.
- **Cho BS**, Min GJ, Park S, Park SS, Shin SH, Yahng SA, Jeon YW, Yoon JH, Lee SE, Eom KS, Kim YJ, Lee S, Min CK, Cho SG, Kim DW, Lee JW, Kim M, Kim Y, Kim HJ. Haploidentical vs matched unrelated donor transplantation for acute myeloid leukemia in remission: A prospective comparative study. *Am J Hematol*. 2021 Jan;96(1):98-109.
- Kim BR, Jung SH, Han AR, Park G, Kim HJ, Yuan B, Battula VL, Andreeff M, Konopleva M, Chung YJ, **Cho BS**. CXCR4 Inhibition Enhances Efficacy of FLT3 Inhibitors in FLT3-Mutated AML Augmented by Suppressed TGF- β Signaling. *Cancers (Basel)*. 2020 Jun 30;12(7):1737.
- Min GJ, **Cho BS**, Park SS, Park S, Jeon YW, Yahng SA, Shin SH, Yoon JH, Lee SE, Eom KS, Kim YJ, Lee S, Min CK, Cho SG, Kim DW, Lee JW, Kim HJ. Safety and efficacy of arsenic trioxide and all-trans retinoic acid therapy in acute promyelocytic leukemia patients with a high risk for early death. *Ann Hematol*. 2020 May;99(5):973-982.
- **Cho BS**, Min GJ, Park SS, Shin SH, Yahng SA, Jeon YW, Yoon JH, Lee SE, Eom KS, Kim YJ, Lee S, Min CK, Cho SG, Kim DW, Lee JW, Kim M, Kim Y, Kim HJ. WT1 Measurable Residual Disease Assay in Patients With Acute Myeloid Leukemia Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation: Optimal Time Points, Thresholds, and Candidates. *Biol Blood Marrow Transplant*. 2019 Oct;25(10):1925-1932.
- **Cho BS**, Jeon YW, Hahn AR, Lee TH, Park SS, Yoon JH, Lee SE, Eom KS, Kim YJ, Lee S, Min CK, Cho SG, Lee JW, Min WS, Kim HJ. Improved survival outcomes and restoration of graft-vs-leukemia effect by deferasirox after allogeneic stem cell transplantation in acute myeloid leukemia. *Cancer Med*. 2019 Feb;8(2):501-514
- Jung J, **Cho BS**, Kim HJ, Han E, Jang W, Han K, Lee JW, Chung NG, Cho B, Kim M, Kim Y. Reclassification of Acute Myeloid Leukemia According to the 2016 WHO Classification. *Ann Lab Med*. 2019 May;39(3):311-316.